Clinical Trials ·
Retatrutide is being evaluated for its effects on kidney function in patients with chronic kidney disease (CKD). The TRANSCEND-CKD trial aims to provide insights into the mechanistic effects of retatrutide on kidney health, particularly in individuals with overweight or obesity and varying degrees of CKD. This trial is crucial for understanding how retatrutide may influence kidney function and related pathophysiological pathways.
What this source covers
The source outlines the rationale, design, and baseline characteristics of the TRANSCEND-CKD trial, a Phase 2b clinical study investigating the efficacy of retatrutide in adults with CKD and obesity. Participants, aged approximately 65 years, were randomized to receive either retatrutide or a placebo, with the primary objective being to assess changes in measured glomerular filtration rate (mGFR) over a 24-week period. The study also aims to evaluate kidney hemodynamic and volumetric changes through MRI assessments.
Why it matters for Retatrutide research
The findings from the TRANSCEND-CKD trial are significant for retatrutide research as they may elucidate the drug's potential benefits beyond weight loss and glycemic control in patients with CKD. Understanding the mechanisms by which retatrutide affects kidney function could inform future clinical applications and therapeutic strategies for managing CKD in conjunction with obesity and type 2 diabetes. This research aligns with ongoing efforts to explore the multifaceted roles of GLP-1, GIP, and glucagon receptor agonists in metabolic and renal health.
Key findings or claims
- TRANSCEND-CKD is a double-blind, placebo-controlled trial.
- Participants include adults with CKD and obesity, with an eGFR of 25-75 mL/min/1.73 m².
- The primary outcome is the change in mGFR assessed by iohexol clearance from baseline to Week 24.
- Secondary outcomes involve MRI assessments of kidney hemodynamics and fat measurements.
- Of the 367 screened participants, 146 were randomized, with a mean age of 65.1 years.
- 37.7% of participants had type 2 diabetes, with a mean HbA1c of 7.1%.
Context and prior work
Retatrutide functions as an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors, which have shown promise in reducing weight and improving glycemic control in individuals with obesity and type 2 diabetes. Prior research has indicated that these pathways may also play a role in influencing renal function, particularly in patients with CKD. The TRANSCEND-CKD trial seeks to build on this existing body of literature by providing mechanistic insights that could enhance understanding of retatrutide's broader implications for kidney health.
Practical takeaways for researchers
Researchers should consider the implications of the TRANSCEND-CKD trial findings for the development of therapeutic strategies targeting CKD in patients with obesity and type 2 diabetes. The trial's design and objectives may serve as a model for future studies exploring the intersection of metabolic and renal health. Additionally, the ongoing evaluation of retatrutide's effects on kidney function could inform clinical practices and guidelines in managing patients with complex comorbidities.
FAQ
What is the primary objective of the TRANSCEND-CKD trial?
The primary objective is to evaluate the effect of retatrutide versus placebo on the change in measured glomerular filtration rate (mGFR) by iohexol clearance from baseline to Week 24.
Who are the participants in the TRANSCEND-CKD trial?
Participants include adults with overweight or obesity and chronic kidney disease, with an estimated glomerular filtration rate (eGFR) between 25-75 mL/min/1.73 m².
What are the secondary outcomes of the trial?
Secondary outcomes include changes in MRI-assessed kidney hemodynamic and volumetric measurements, including perirenal and renal sinus fat.
Source: PubMed · Nephrol Dial Transplant · published 2025-10-29.